ASMB ASSEMBLY BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1426800 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.2%
TTM net income YoY71.2%
TTM EPS YoY116.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-31.8%
Net margin-16.6%
FCF margin-60.7%
EBITDA margin-31.7%
Returns
ROE-4.6%
ROA-3.9%
ROIC (approx.)-7.8%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets8.1%
Debt / equity0.00x
Current ratio12.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.65x
Accruals ratio10.4%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $72.30M | $28.52M | $7.16M | $0 | $6.25M |
| R&D expense | $64.81M | $55.93M | $48.90M | $69.98M | $68.52M |
| SG&A expense | $19.61M | $18.01M | $22.91M | $24.13M | $28.78M |
| Operating income | -$12.12M | -$45.42M | -$64.65M | -$94.11M | -$132.69M |
| Pretax income | -$6.12M | -$39.85M | -$61.20M | -$93.09M | -$132.39M |
| Income tax | $0 | $330,000 | $33,000 | $0 | -$2.53M |
| Net income | -$6.12M | -$40.18M | -$61.23M | -$93.09M | -$129.85M |
| EBITDA | -$11.99M | -$45.29M | -$64.20M | -$93.62M | -$132.22M |
| EPS (basic) | -0.55 | -6.69 | -13.38 | -23.08 | -3.00 |
| EPS (diluted) | -0.55 | -6.69 | -13.38 | -23.08 | -3.00 |
| Weighted avg. shares (diluted) | 11.21M | 6.00M | 4.58M | 4.03M | 43.28M |
| Balance sheet | |||||
| Cash & equivalents | $58.45M | $38.34M | $19.84M | $52.42M | $45.63M |
| Short-term investments | $189.66M | $73.73M | $110.41M | $39.19M | $101.00M |
| Receivables | $974,000 | $0 | $43,000 | $944,000 | $336,000 |
| Current assets | $254.55M | $115.50M | $133.79M | $96.97M | $154.20M |
| PP&E, net | $221,000 | $284,000 | $385,000 | $743,000 | $1.14M |
| Total assets | $257.59M | $119.17M | $136.82M | $101.79M | $191.06M |
| Current liabilities | $48.78M | $47.80M | $39.23M | $16.30M | $16.07M |
| Total liabilities | $50.84M | $85.81M | $95.73M | $19.13M | $22.13M |
| Shareholders' equity | $206.75M | $33.36M | $41.10M | $82.66M | $168.93M |
| Shares outstanding | 15.86M | 7.46M | 5.48M | 4.07M | 48.12M |
| Cash flow statement | |||||
| Operating cash flow | -$41.09M | -$51.12M | $22.74M | -$84.46M | -$93.40M |
| Capital expenditure | $66,000 | $28,000 | $255,000 | $102,000 | $3.10M |
| Free cash flow | -$41.16M | -$51.15M | $22.49M | -$84.56M | -$96.49M |
| Investing cash flow | -$113.47M | $40.17M | -$69.14M | $90.64M | $26.52M |
| Financing cash flow | $174.67M | $29.45M | $13.82M | $614,000 | $53.06M |
| Depreciation & amortization | $129,000 | $129,000 | $450,000 | $498,000 | $466,000 |
| Stock-based compensation | $4.68M | $3.12M | $5.12M | $6.59M | $5.24M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.